PDCD1 and melanoma: These findings are surprising for the melanoma cohort since anti‐PD‐1 monotherapy has been shown in previously untreated patients to improve outcomes over anti‐CLTA4 monotherapy49 and was more often prescribed in this dataset than anti‐CLTA‐4 monotherapy.